Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III emicizumab prophylaxis in pediatric hemophilia A with FVIII inhibitors
jRCT2080223243Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2016
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Efficacy of emicizumab prophylaxis, Safety and tolerability and 1 more. Started Jun 2016; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080223243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223243.